Global Pharmerging Markets 2017-2021 - Product Image

Global Pharmerging Markets 2017-2021

  • ID: 4039551
  • Report
  • Region: Global
  • 116 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CSL Behring
  • Gilead
  • Menarini
  • Sanofi
  • MORE
About Pharmerging

The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

The analysts forecast the global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global pharmerging market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of pharmaceutical drugs in pharmerging markets, which are further divided into Tier I, II and III.

The market is divided into the following segments based on geography:

- Tier 1
- Tier 2
- Tier 3

The report, Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- Sanofi
- Novartis

Other prominent vendors
- Abbott Laboratories
- AbbVie
- Alexion Pharmaceuticals
- Allergan
- Amgen
- Aspen
- Astellas Pharma
- Baxter
- Bayer
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- CSL Behring
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly
- Endo Health Pharmaceuticals
- F. Hoffmann-La Roche
- Fresenius
- Gilead
- Grifols
- H. Lundbeck
- Hospira
- Johnson & Johnson
- Kyowa Hakko Kirin
- Mallinckrodt Pharmaceuticals
- Menarini
- Mitsubishi Tanabe Pharma
- Mylan
- Novo Nordisk
- Otsuka
- Shire
- STADA Arzneimittel
- Sun Pharmaceutical
- Takeda Pharma
- Teva Pharmaceutical Industries
- UCB
- Valeant Pharmaceuticals

Market drivers
- Limitations in developed economies fuels demand in emerging economies
- For a full, detailed list, view the full report

Market challenges
- Stringent price control and generic -centric usage lead to value erosion
- For a full, detailed list, view the full report

Market trends
- Potential of new countries in emerging markets
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CSL Behring
  • Gilead
  • Menarini
  • Sanofi
  • MORE
Part 01: Executive summary

Part 02: Scope of the report
  • Market overview
Part 03: Market research methodology
  • Research methodology
  • Economic indicators
Part 04: Introduction
  • Key market highlights
  • Highlights
Part 05: Global pharmaceutical market
  • Market size and forecast
Part 06: Road to pharmerging markets

Part 07: Pharmerging markets

Part 08: Market landscape
  • Medicine spending in emerging economies
  • Five forces analysis
Part 09: Market segmentation by geography

Part 10: Market overview of tier I countries
  • China
Part 11: Market overview of tier II countries
  • Brazil
  • Russia
  • India
Part 12: Market overview of tier III countries
  • Market size and forecast
Part 13: Market drivers
  • Limitations in developed economies fuels demand in emerging economies
  • Increasing focus toward biosimilar in potential areas
  • Expansion initiatives of vendors
Part 14: Impact of drivers

Part 15: Market challenges
  • IP protection issues
  • Socio-political issues in cross geography transactions
  • Stringent price control and generic-centric usage lead to value erosion
Part 16: Impact of drivers and challenges

Part 17: Market trends
  • Potential of new countries in emerging markets
  • Positive outlook toward adoption of targeted therapies
  • Evolving stakeholder landscape to change market dynamics
Part 18: Vendor landscape
  • Competitive scenario
Part 19: Key vendor analysis
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Novartis
  • Other prominent vendors
Part 20: Appendix
  • List of Abbreviations
Part 21: About the Author

List of Exhibits

Exhibit 01: Global country rankings in pharmaceutical market based on healthcare spending
Exhibit 02: Global pharmaceutical market 2016-2021 ($ trillions)
Exhibit 03: Drivers, challenges and trends of global pharmaceutical market
Exhibit 04: Growth comparision between developed markets and pharmerging markets
Exhibit 05: Share of pharmerging markets in global pharmaceutical market, 2016
Exhibit 06: Snapshot of key pharmerging markets
Exhibit 07: Regulatory landscape in key pharmerging markets
Exhibit 08: Pharmerging markets 2016-2021 ($ billions)
Exhibit 09: Comparison of medicine spending in developed economies and pharmerging markets
Exhibit 10: Medicine spending and growth rates in pharmerging markets
Exhibit 11: Standard units in 2021 by product type in pharmerging countries
Exhibit 12: Expected medicine spending by geography
Exhibit 13: Volume growth and population with more than $5,000/year income by country 2016
Exhibit 14: Percentage share of pharmerging markets in global pharmaceutical market 2016-2021
Exhibit 15: Percentage share of tier I, II and III countries in total pharmerging markets 2016-2021
Exhibit 16: Pharmerging markets share by country, 2016
Exhibit 17: Five forces analysis
Exhibit 18: Pharmerging markets segment by geography
Exhibit 19: Geographic representation of tier I country
Exhibit 20: China GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 21: On-going healthcare reforms in China
Exhibit 22: Segmentation of Chinese pharmaceutical market
Exhibit 23: Segment analysis in Chinese pharmaceutical market
Exhibit 24: Regulatory bodies
Exhibit 25: Major therapy areas based on sales of drugs, 2016
Exhibit 26: Major acquisitions in Chinese pharmaceutical market 2014-2016
Exhibit 27: Drivers and challenges in Chinese pharmaceutical market
Exhibit 28: Pharmaceutical market in China 2016-2021 ($ billions)
Exhibit 29: China pharmaceutical market: SWOT analysis
Exhibit 30: Geographic representation of tier II countries
Exhibit 31: Pharmaceutical market in tier II countries 2016-2021 ($ billions)
Exhibit 32: Brazil GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 33: Regulatory bodies
Exhibit 34: Segmentation of pharmaceutical market in Brazil 2016
Exhibit 35: Major acquisitions in Brazil pharmaceutical market
Exhibit 36: Drivers and challenges in Brazilian pharmaceutical market
Exhibit 37: Pharmaceutical market in Brazil 2016-2021 ($ billions)
Exhibit 38: Brazil pharmaceutical market: SWOT analysis
Exhibit 39: Russia GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 40: Major acquisitions in Russian pharmaceutical market
Exhibit 41: Drivers and challenges in Russian pharmaceutical market
Exhibit 42: Pharmaceutical market in Russia 2016-2021 ($ billions)
Exhibit 43: Russia pharmaceutical market: SWOT analysis
Exhibit 44: India GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 45: Regulatory landscape
Exhibit 46: Major acquisitions in pharmaceutical sector in India
Exhibit 47: Drivers and challenges in Indian pharmaceutical market
Exhibit 48: Pharmaceutical market in India 2016-2021 ($ billions)
Exhibit 49: India pharmaceutical market: SWOT analysis
Exhibit 50: Geographic representation of tier III countries
Exhibit 51: Pharmaceutical market in tier III countries 2016-2021 ($ billions)
Exhibit 52: Revenues from pharmaceuticals for few of the tier III countries 2016 ($ billions)
Exhibit 53: Snapshot of key countries in tier III countries
Exhibit 54: Tier III countries pharmaceutical market: SWOT analysis
Exhibit 55: Factors that are driving the growth in emerging economies
Exhibit 56: Biosimilar development in emerging economies
Exhibit 57: Few acquisitions and their impact
Exhibit 58: Impact of drivers
Exhibit 59: Impact of drivers and challenges
Exhibit 60: Positioning of key vendors in pharmerging markets 2015
Exhibit 61: Competitive analysis snapshot
Exhibit 62: Top selling products in emerging markets 2015
Exhibit 63: Key takeaways
Exhibit 64: Key highlights in emerging markets
Exhibit 65: AstraZeneca strength assessment
Exhibit 66: Geographic segmentation by revenue 2015
Exhibit 67: Key takeaways
Exhibit 68: Key highlights in emerging markets
Exhibit 69: GSK strength assessment
Exhibit 70: Geographic segmentation by revenue 2015
Exhibit 71: Key takeaways
Exhibit 72: Pfizer: YoY and growth rate in emerging markets
Exhibit 73: Segmentation by revenue in emerging markets ($ millions)
Exhibit 74: Key highlights in emerging markets
Exhibit 75: Pfizer strength assessment
Exhibit 76: Pfizer: Geographical segmentation by revenue 2015
Exhibit 77: Top selling products0
Exhibit 78: Key emerging products0
Exhibit 79: Geographical segmentation by revenue1
Exhibit 80: Key takeaways2
Exhibit 81: Key highlights in emerging markets2
Exhibit 82: Sanofi strength assessment3
Exhibit 83: Key takeaways4
Exhibit 84: Key highlights in emerging markets5
Exhibit 85: Novartis strength assessment6
Exhibit 86: Novartis: Geographical segmentation by revenue 20156
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CSL Behring
  • Gilead
  • Menarini
  • Sanofi
  • MORE
New Report Released: - Global Pharmerging Market 2017-2021

The author of the report recognizes the following companies as the key players in the global pharmerging market: AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi, and Novartis

Other Prominent Vendors in the market are: Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical Industries, UCB, and Valeant Pharmaceuticals

Commenting on the report, an analyst from the research team said: “Although the adoption of targeted therapies in emerging markets is low, it is expected to increase substantially during the forecast period, particularly in the long term. With the growing incidence of chronic diseases such as cancer, which requires specific therapies for the effective treatment, the adoption of targeted therapies is expected to witness substantial upward momentum. For instance, in India, the prevalence of cancer is expected to increase by 25%-40% in the next 10 years. The increasing awareness among physicians about the advantages of targeted therapies will certainly lead to an increase in adoption rates. Research studies done across the geographies have demonstrated that targeted therapy has increased the survival rate and the cure rate in cancer patients. These drugs are expected to work effectively in the treatment of various cancers such as lung cancer, breast cancer, chronic myeloid leukemia and lymphomas. Although, the cost of these targeted therapies is higher than the traditional ones, the growing awareness toward government subsidies and reimbursements could improve the adoption of such therapies even in the pharmerging nations. For instance, many states in India such as Gujarat, and Chattisgarh are providing such drugs at free of cost. Also, the leading players such as Novartis have implemented patient assistance programs to increase the affordability of Gleevec (a treatment for chronic myelogenous leukaemia) in India.”

According to the report, the pharmaceutical market in developed economies has reached its maturity phase and hence, is witnessing stagnance in terms of growth. This is primarily due the unfavorable economic conditions and patent expiries of innovator products. In order to maintain a healthy growth trajectory, the companies started exploring for new sources of revenue. In addition, the healthcare budget cuts in developed markets such as the US, has further driven the vendors' focus toward emerging economies. For instance, in March 2016, the US government repealed the Affordable Care Act, which results in the shutdown of health insurance, and financial assistance for insurance. This plan would end the Medicaid expansion by eliminating the federal funding that earlier enabled to expand health coverage to millions of adults. Further, the plan would radically restructure the traditional Medicaid program leading to more than $1.8 trillion decline in healthcare spending. As these markets have largely been oriented to reimbursement structure, the patients are not comfortable with out of pocket scenario. Such radical cuts in healthcare expenditure hurts the growth of pharmaceutical vendors despite being defensive in nature, as patients/healthcare providers look for cheaper alternatives.

Further, the report states that IP protection issues significantly influence the go-to-market strategies and tactics of the global pharmaceutical companies. For instance, the Indian government supports generic companies to provide end-users with affordable medication. The support is provided even when it goes against current patent laws and related rules of the World Trade Organization. For instance, Bayer HealthCare's Nexavar, a drug for hepatocellular carcinoma faces competition from Natco Pharma and due to the inability to afford the drug among the general population, the Indian government has given Natco, the manufacturing and marketing rights for the drug. Natco pays only 6% in royalties and is able to offer Nexavar approximately $170 per month, while Bayer HealthCare's Nexavar drug costs $5,500 per month. Bayer HealthCare eventually offered the drug at a reduced product price (almost 10% of original therapy costs), but on the condition that decreased prices are available only to those individuals diagnosed by licensed oncologists. The lack of proper guidelines for IP protection have fuelled the counterfeit products in emerging economies particularly in Africa. In Sub Saharan African countries, the share of counterfeit pharma drugs is close to 50%.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Novartis
  • Abbott Laboratories
  • AbbVie
  • Alexion Pharmaceuticals
  • Allergan
  • Amgen
  • Aspen
  • Astellas Pharma
  • Baxter
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • CSL Behring
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Eisai
  • Eli Lilly
  • Endo Health Pharmaceuticals
  • F. Hoffmann-La Roche
  • Fresenius
  • Gilead
  • Grifols
  • H. Lundbeck
  • Hospira
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Mallinckrodt Pharmaceuticals
  • Menarini
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Novo Nordisk
  • Otsuka
  • Shire
  • STADA Arzneimittel
  • Sun Pharmaceutical
  • Takeda Pharma
  • Teva Pharmaceutical Industries
  • UCB
  • Valeant Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll